Reactive oxygen species-responsive virus-mimicking nanodrug for the treatment of influenza A virus infection

IF 5.6 2区医学 Q1 BIOPHYSICS

Colloids and Surfaces B: Biointerfaces Pub Date : 2025-08-30 DOI:10.1016/j.colsurfb.2025.115090

Hong-Li Wang , ChuanMing Yu , Qiangling Yin , Jin-Wei Bu , Shuang Feng , Di Ning , Shu-Lin Liu , Linlin Liu , Zhi-Gang Wang

{"title":"Reactive oxygen species-responsive virus-mimicking nanodrug for the treatment of influenza A virus infection","authors":"Hong-Li Wang , ChuanMing Yu , Qiangling Yin , Jin-Wei Bu , Shuang Feng , Di Ning , Shu-Lin Liu , Linlin Liu , Zhi-Gang Wang","doi":"10.1016/j.colsurfb.2025.115090","DOIUrl":null,"url":null,"abstract":"<div><div>Drug therapy is an important measure to reduce the morbidity and mortality of influenza. However, small molecule drugs have inherent limitations, such as poor water solubility, non-specific biological distribution, and susceptibility to degradation during blood circulation, which impose a great burden on patients, both physically and mentally. Inspired by the high levels of reactive oxygen species (ROS) at the site of influenza A virus (IAV) infection, we have developed an intelligent responsive virus-mimicking nanodrug (Zana@HA-Lip) based on a biomimetic approach, reduces the damage of the drug to normal tissues or organs while achieving the purpose of antiviral therapy by precisely releasing the drug at the lesion site. Zana@HA-Lip offers distinct advantages regarding lesion site tropism, duration of action, and efficiency of release in response to ROS. This work not only presents a safe and effective strategy for alleviating lung injury caused by IAV infection but also introduces a new concept for the precise customization of virus-mimicking nanocarriers.</div></div>","PeriodicalId":279,"journal":{"name":"Colloids and Surfaces B: Biointerfaces","volume":"257 ","pages":"Article 115090"},"PeriodicalIF":5.6000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloids and Surfaces B: Biointerfaces","FirstCategoryId":"1","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0927776525005971","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOPHYSICS","Score":null,"Total":0}

引用次数: 0

Abstract

Drug therapy is an important measure to reduce the morbidity and mortality of influenza. However, small molecule drugs have inherent limitations, such as poor water solubility, non-specific biological distribution, and susceptibility to degradation during blood circulation, which impose a great burden on patients, both physically and mentally. Inspired by the high levels of reactive oxygen species (ROS) at the site of influenza A virus (IAV) infection, we have developed an intelligent responsive virus-mimicking nanodrug (Zana@HA-Lip) based on a biomimetic approach, reduces the damage of the drug to normal tissues or organs while achieving the purpose of antiviral therapy by precisely releasing the drug at the lesion site. Zana@HA-Lip offers distinct advantages regarding lesion site tropism, duration of action, and efficiency of release in response to ROS. This work not only presents a safe and effective strategy for alleviating lung injury caused by IAV infection but also introduces a new concept for the precise customization of virus-mimicking nanocarriers.

查看原文本刊更多论文

治疗甲型流感病毒感染的活性氧反应型病毒模拟纳米药物

药物治疗是降低流感发病率和死亡率的重要措施。然而，小分子药物存在固有的局限性，如水溶性差、非特异性生物分布、在血液循环过程中容易降解等，给患者的身体和精神都带来了很大的负担。受甲型流感病毒（IAV）感染部位高水平活性氧（ROS）的启发，我们开发了一种基于仿生方法的智能反应型病毒模拟纳米药物（Zana@HA-Lip），减少了药物对正常组织或器官的损伤，同时通过在病变部位精确释放药物达到抗病毒治疗的目的。Zana@HA-Lip在病变部位趋向性、作用持续时间和ROS释放效率方面具有明显优势。这项工作不仅为减轻IAV感染引起的肺损伤提供了一种安全有效的策略，而且为精确定制模拟病毒的纳米载体引入了一种新概念。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colloids and Surfaces B: Biointerfaces 生物-材料科学：生物材料

CiteScore

11.10

自引率

3.40%

发文量

730

审稿时长

42 days

期刊介绍： Colloids and Surfaces B: Biointerfaces is an international journal devoted to fundamental and applied research on colloid and interfacial phenomena in relation to systems of biological origin, having particular relevance to the medical, pharmaceutical, biotechnological, food and cosmetic fields. Submissions that: (1) deal solely with biological phenomena and do not describe the physico-chemical or colloid-chemical background and/or mechanism of the phenomena, and (2) deal solely with colloid/interfacial phenomena and do not have appropriate biological content or relevance, are outside the scope of the journal and will not be considered for publication. The journal publishes regular research papers, reviews, short communications and invited perspective articles, called BioInterface Perspectives. The BioInterface Perspective provide researchers the opportunity to review their own work, as well as provide insight into the work of others that inspired and influenced the author. Regular articles should have a maximum total length of 6,000 words. In addition, a (combined) maximum of 8 normal-sized figures and/or tables is allowed (so for instance 3 tables and 5 figures). For multiple-panel figures each set of two panels equates to one figure. Short communications should not exceed half of the above. It is required to give on the article cover page a short statistical summary of the article listing the total number of words and tables/figures.